You searched for "Penis"
In conversation with Mr Duncan Summerton
Urology News was delighted to recently have a chat with Duncan Summerton, Consultant Urological Surgeon in Leicester and new President of BAUS. Duncan with a native wild brown trout caught on a dry fly on the Derbyshire Wye. Can you...
Adjustable Transobturator Male System® as a novel treatment for men with stress urinary incontinence
Stress urinary incontinence (SUI) in men is a debilitating condition, often occurring after prostate cancer surgery, with an incidence ranging from 4% to 40%. Key predictors of SUI post-prostatectomy include age, body mass index (BMI), comorbidity index, lower urinary tract...PROFILE study seeks to find out why black men develop prostate cancer at twice the rate of other men
A first-of-its-kind study in the UK is aiming to solve the mystery of why black men develop prostate cancer at twice the rate of other men. Funded by Prostate Cancer UK in partnership with Movember, the PROFILE study will look...The aero-urethroscope
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). In the last article I said I would write about another old urological...EAU Pocket Guidelines App
The European Association of Urology (EAU) has consistently led on the latest guidelines and advanced the care of urology since its inception. The EAU Pocket Guidelines app provides pocket guideline summaries of the full EAU Guidelines collection. The app is...The process of medical innovation – evolving trends and future perspectives
In 2018 the United Kingdom Government spending on healthcare totalled almost £166 billion. Of this approximately 65% was attributed to providing curative or rehabilitation therapy, with health-related long-term care and provision of goods accounting for 25%. The remaining was accredited...
One cycle of adjuvant chemotherapy in tumours of the testis
Following a radical orchiectomy, current UK practice for newly diagnosed, high-risk, stage 1 nonseminomatous or combined germ cell tumours of the testis (NSCGCTT) is either two cycles of adjuvant chemotherapy with bleomycin, etoposide, cisplatin (BE360Px2) or surveillance with BE500Px3 on...
